http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#Head
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#assertion
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#provenance
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#pubinfo
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#assertion
http://purl.obolibrary.org/obo/DOID_5844
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_5844
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00934
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
http://www.w3.org/2000/01/rdf-schema#label
Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction.
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00934
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#provenance
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#pubinfo
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig
http://purl.org/nanopub/x/hasSignature
dhZfRc575bxoQOZR46xb/A1hQM30wLNF885Gm4fvlaKxveGcWkp+GLZY8t9crRv8EWNNVxnevOI2+8hO/puL8insACSBw3USa8YrpMSJlMf44+hIaeP0mpXQ8SfkSeAKfDK1jS3U15hzJaULewrVDSf/m71SP1Dy9j0AE/6gSBs=
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://purl.org/dc/terms/created
2021-08-25T14:13:30.145+02:00
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY